Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) were trading largely flat post-market Monday after the biotech company released its Q4 earnings report and issued 2025 guidance that was largely in line ...

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported fourth-quarter profit of $913 million. The Boston-based company said it had net income of $3.50 per share. Earnings, ...

By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

Learn more about whether Pegasystems Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...